IL5 and chronic obstructive pulmonary disease: In recent times, given the growing acknowledgment of the role of T2 inflammation in COPD [50], some promising findings of trials with anti-IL-5/5Rα biologics in this clinical setting are noteworthy, with further insights expected from the ongoing MATINEE (NCT04133909) and SUMMER (NCT05138250) on mepolizumab or RESOLUTE (NCT04053634) on benralizumab.